Viking Therapeutics Charts a Course in Long-Term Weight Management

Viking Therapeutics completes enrollment for its Phase 3 obesity drug trial, backed by strong finances and a strategy focused on flexible, long-term treatment regimens.

Within the lucrative anti-obesity drug market, Viking Therapeutics is emerging as a formidable competitor. The company's strategic focus on sustained treatment is gaining tangible momentum, drawing positive attention from investors. This approach, which emphasizes flexible dosing regimens to differentiate from existing therapies, is moving closer to realization following a key operational achievement.

Financial Backing and Portfolio Expansion

A solid financial foundation underpins Viking's ambitious clinical programs. As of the close of the last quarter, the company reported cash reserves of approximately $706 million. This substantial war chest is deemed sufficient to fund both the ongoing VANQUISH trial series and the planned initiation of an oral Phase 3 program later this year.

Beyond its core obesity pipeline, Viking is actively diversifying its research efforts. Progress continues with the liver-targeted candidate VK2809, while plans are advancing to file for a clinical study of a novel amylin agonist. This strategy positions the company with a broader portfolio in one of the pharmaceutical industry's most dynamic growth sectors.

VANQUISH-2 Trial Reaches Enrollment Milestone

A recent operational milestone catalyzed a share price advance of about 5.6% to nearly $35. Viking Therapeutics has successfully completed patient recruitment for its pivotal Phase 3 study, VANQUISH-2. This trial involves roughly 1,000 adults living with obesity and type 2 diabetes, who are testing a subcutaneous (injected) formulation of the investigational drug VK2735.

Participants will be treated over a 78-week period with varying doses of up to 17.5 milligrams or a placebo. The primary focus is on measuring the percentage change in body weight. Management anticipates the first robust data from this program to become available starting in 2027.

Strategic Emphasis on Dosing Flexibility and Maintenance

Viking's development strategy extends beyond initial weight reduction to prioritize long-term weight maintenance. A current Phase 1 study is evaluating different maintenance dosing schedules. Results expected in the third quarter of 2026 are designed to demonstrate how effectively patients can transition between injectable and oral tablet forms of the therapy. Market observers see this potential for flexible regimens—such as combining a monthly injection with daily or weekly pills—as a distinct competitive edge against established treatments.

To further advance the oral tablet version, Viking is preparing to launch its own dedicated Phase 3 program in Q3 of this year. The company is adapting its dosing strategy for this effort, implementing an optimized, stepwise escalation of the starting dose. This adjustment aims to enhance patient tolerability without compromising the high efficacy observed in earlier studies.